- Home
- ARCO vs IDYA Comparison
ARCO vs IDYA Comparison
Compare ARCO & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARCO
- IDYA
- Stock Information
- Founded
- ARCO 2007
- IDYA 2015
- Country
- ARCO Uruguay
- IDYA United States
- Employees
- ARCO N/A
- IDYA N/A
- Industry
- ARCO Restaurants
- IDYA Biotechnology: Pharmaceutical Preparations
- Sector
- ARCO Consumer Discretionary
- IDYA Health Care
- Exchange
- ARCO Nasdaq
- IDYA Nasdaq
- Market Cap
- ARCO 1.5B
- IDYA 1.5B
- IPO Year
- ARCO 2011
- IDYA 2019
- Fundamental
- Price
- ARCO $7.58
- IDYA $19.00
- Analyst Decision
- ARCO Buy
- IDYA Strong Buy
- Analyst Count
- ARCO 1
- IDYA 13
- Target Price
- ARCO $12.00
- IDYA $53.58
- AVG Volume (30 Days)
- ARCO 2.3M
- IDYA 1.7M
- Earning Date
- ARCO 05-14-2025
- IDYA 05-06-2025
- Dividend Yield
- ARCO 3.21%
- IDYA N/A
- EPS Growth
- ARCO N/A
- IDYA N/A
- EPS
- ARCO 0.71
- IDYA N/A
- Revenue
- ARCO $4,470,162,000.00
- IDYA $7,000,000.00
- Revenue This Year
- ARCO $6.66
- IDYA $121.20
- Revenue Next Year
- ARCO $8.58
- IDYA $302.20
- P/E Ratio
- ARCO $10.64
- IDYA N/A
- Revenue Growth
- ARCO 3.19
- IDYA N/A
- 52 Week Low
- ARCO $6.66
- IDYA $13.45
- 52 Week High
- ARCO $11.49
- IDYA $44.42
- Technical
- Relative Strength Index (RSI)
- ARCO 49.97
- IDYA 59.35
- Support Level
- ARCO $6.88
- IDYA $15.84
- Resistance Level
- ARCO $7.77
- IDYA $20.08
- Average True Range (ATR)
- ARCO 0.35
- IDYA 1.36
- MACD
- ARCO 0.05
- IDYA 0.50
- Stochastic Oscillator
- ARCO 82.43
- IDYA 83.71
About ARCO Arcos Dorados Holdings Inc. Shares
Arcos Dorados Holdings Inc operates McDonald's-branded restaurants in approximately 20 countries and territories in Latin America and the Caribbean. It functions through two sources which include company-operated restaurants and franchised restaurants segment. Their menu includes hamburgers, McNuggets, salad, sandwiches, french fries and others.
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.